FILE - In this Jan. 26, 2010 file photo Daniel Vasella, chairman of the board of Swiss pharmaceutical group Novartis, speaks during the annual results conference in Basel, Switzerland. The outgoing chairman of Swiss drug maker Novartis AG has agreed to cancel a much-criticized deal under which he stood to earn up to 72 million francs (US dollar 78 million) for not advising competitors over the coming years. The company's long-time chairman and former chief executive, is to step down at its annual general meeting on Feb. 22. (AP Photo/Keystone, Georgios Kefalas, File)

Associated Press
FILE - In this Jan. 26, 2010 file photo Daniel Vasella, chairman of the board of Swiss pharmaceutical group Novartis, speaks during the annual results conference in Basel, Switzerland. The outgoing chairman of Swiss drug maker Novartis AG has agreed to cancel a much-criticized deal under which he stood to earn up to 72 million francs (US dollar 78 million) for not advising competitors over the coming years. The company's long-time chairman and former chief executive, is to step down at its annual general meeting on Feb. 22. (AP Photo/Keystone, Georgios Kefalas, File)
FILE - In this Jan. 26, 2010 file photo Daniel Vasella, chairman of the board of Swiss pharmaceutical group Novartis, speaks during the annual results conference in Basel, Switzerland. The outgoing chairman of Swiss drug maker Novartis AG has agreed to cancel a much-criticized deal under which he stood to earn up to 72 million francs (US dollar 78 million) for not advising competitors over the coming years. The company's long-time chairman and former chief executive, is to step down at its annual general meeting on Feb. 22. (AP Photo/Keystone, Georgios Kefalas, File)